Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2022

May 16, 2022

SELL
$30.27 - $49.22 $5.37 Million - $8.73 Million
-177,294 Closed
0 $0
Q4 2021

Feb 14, 2022

BUY
$42.11 - $73.26 $5.65 Million - $9.82 Million
134,067 Added 310.15%
177,294 $8.76 Million
Q3 2021

Nov 15, 2021

BUY
$48.2 - $78.89 $2.08 Million - $3.41 Million
43,227 New
43,227 $3.08 Million
Q2 2021

Aug 16, 2021

SELL
$21.63 - $57.65 $6.79 Million - $18.1 Million
-313,851 Closed
0 $0
Q1 2021

May 17, 2021

SELL
$11.0 - $28.24 $21,340 - $54,785
-1,940 Reduced 0.61%
313,851 $7.88 Million
Q4 2020

Feb 16, 2021

SELL
$10.12 - $13.94 $25,431 - $35,031
-2,513 Reduced 0.79%
315,791 $3.79 Million
Q3 2020

Nov 16, 2020

SELL
$9.93 - $13.47 $145,126 - $196,864
-14,615 Reduced 4.39%
318,304 $3.18 Million
Q2 2020

Aug 17, 2020

BUY
$9.56 - $12.51 $1,940 - $2,539
203 Added 0.06%
332,919 $3.48 Million
Q1 2020

May 15, 2020

BUY
$7.54 - $15.77 $138,668 - $290,026
18,391 Added 5.85%
332,716 $3.56 Million
Q4 2019

Feb 14, 2020

BUY
$7.48 - $17.01 $183,357 - $416,966
24,513 Added 8.46%
314,325 $4.98 Million
Q3 2019

Nov 14, 2019

BUY
$6.89 - $10.45 $320,529 - $486,144
46,521 Added 19.12%
289,812 $2.27 Million
Q2 2019

Aug 13, 2019

BUY
$8.85 - $12.49 $803,606 - $1.13 Million
90,803 Added 59.55%
243,291 $2.57 Million
Q1 2019

May 14, 2019

BUY
$10.32 - $14.49 $1.08 Million - $1.51 Million
104,313 Added 216.53%
152,488 $1.85 Million
Q4 2018

Feb 14, 2019

BUY
$8.73 - $13.74 $420,567 - $661,924
48,175 New
48,175 $496,000

Others Institutions Holding PRTA

About PROTHENA CORP PUBLIC LTD CO


  • Ticker PRTA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 46,922,800
  • Market Cap $710M
  • Description
  • Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing Birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a human...
More about PRTA
Track This Portfolio

Track Jacobs Levy Equity Management, Inc Portfolio

Follow Jacobs Levy Equity Management, Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Jacobs Levy Equity Management, Inc, based on Form 13F filings with the SEC.

News

Stay updated on Jacobs Levy Equity Management, Inc with notifications on news.